Gregory Scott's Biography

Home
|
Register
|
Submissions
- Submission Guidelines
- Submissions
|
Agenda
|
Exhibition
|
Venue
|
Media
|

Gregory Scott, Patent Attorney, Klarquist Sparkman, LLP

Dr. Scott is a patent attorney at Klarquist Sparkman, LLP in Portland, Oregon, where he prepares and prosecutes U.S. and International patent applications, and advises clients about patent portfolio management, freedom-to-operate, and strategic product development. His technical experience includes applications related to biochemistry, molecular genetics, virology, immunology, and neurobiology. Dr. Scott’s practice emphasis is in biotechnology, including applications relating to biologic drugs and their use, and diagnostic methods involving exosome and DNA expression profiling.

Biomarker Patents after Prometheus and Myriad

Friday, 19 September 2014 at 18:15

Add to Calendar ▼2014-09-19 18:15:002014-09-19 19:15:00Europe/LondonBiomarker Patents after Prometheus and MyriadExosomes and Single Cell Analysis Summit in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

The Supreme Court’s decisions in Prometheus and Myriad shifted the biomarker IP landscape by raising the bar to obtain meaningful patent protection for diagnostic methods involving biomarker detection. After two years of uncertainty, the Patent Office and Courts are beginning to offer guidance on how to apply the Prometheus and Myriad standards. I will review these recent legal developments and describe current approaches we are using to obtain patent claims to diagnostic methods.

Add to Calendar ▼2014-09-18 00:00:002014-09-19 00:00:00Europe/LondonExosomes and Single Cell Analysis SummitExosomes and Single Cell Analysis Summit in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors